RxDoctor Payments DataLook up a doctor →

Andrew Henry, MD

Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1194892141

Payments from drug & device makers

$929,461in general payments, 2019–2025

Across 804 payments — averaging $1156.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$404K
  • Eli Lilly$350K
  • AstraZeneca$88K
  • Intuity Medical Inc$37K
  • Sanofi-aventis U.S. LLC$18K
  • Merck$10K
  • plus $23K from 47 others
$873in research payments, 2019–2025

Across 1 payment — averaging $872.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$873

What the payments were for

  • Speaking & faculty fees$151,56188%
  • Travel & lodging$5,6853%
  • Food & beverage$15,6939%
  • Education$880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$929,461 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$88,593
Medicare patients
373
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide309$474,561
MounjaroTirzepatide190$262,849
Tresiba Flextouch U-100Insulin Degludec140$255,344
FarxigaDapagliflozin Propanediol99$114,942
TradjentaLinagliptin92$97,507
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog66$86,059
JardianceEmpagliflozin59$82,029
JanuviaSitagliptin Phosphate57$80,451
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$73,846
Tresiba Flextouch U-200Insulin Degludec20$64,718
Lantus SolostarInsulin Glargine,hum.Rec.Anlog185$49,448
Humulin R U-500 KwikpenInsulin Regular, Human25$45,593
TrulicityDulaglutide22$45,198
Humalog Kwikpen U-100Insulin Lispro95$42,742
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp66$40,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$1,776$498,017375 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30$9,227$341,661311 claims
Boehringer IngelheimTradjenta, Jardiance$3,079$179,536151 claims
AstraZenecaFarxiga$87,646$114,94299 claims
MerckJanuvia, Janumet$10,451$100,26875 claims
AbbVieSynthroid$367$28,343275 claims
Sanofi-aventis U.S. LLCLantus$17,587$22,00670 claims
PfizerPrempro$25$3,48412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →